Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study
Advances in Medical Sciences · 2026-09 · 71 (2) · 394-401
DOI: 10.1016/j.advms.2026.10.005 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Advances in Medical Sciences, 2026-09. Verfasst von Artur Dziewierz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Department of Cardiology and Cardi…. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Tirzepatide is effective in clinical trials, but its real-world use where obesity pharmacotherapy is self-funded remains poorly characterized. We aimed to characterize tirzepatide persistence, adherence, and dose escalation in a high out-of-pocket-cost setting. PATIENTS AND METHODS: We retrospectively analyzed nationwide electronic health records from a large Polish private healthcare provider. We included 3030 adults with a first recorded tirzepatide prescription between November 2023 and February 2025. The primary endpoint was time to observed treatment discontinuation. Multivariable Cox regression identified persistence predictors, while adherence was assessed using proportion of days covered (PDC). Successful titration was escalation from 2.5 or 5 mg to ≥10 mg. RESULTS: The cohort included 69.0% women; 83.3% had obesity and 20.0% had type 2 diabetes. Higher first recorded dose was associated with earlier loss of observed treatment. Compared with 2.5 mg initiators, the hazard ratio for discontinuation was 1.44 (95%CI 1.26-1.64, p 0.10). Among385 patients persistent for ≥180 days, median PDC was 0.86 (IQR 0.73-0.95), with 68% classified as adherent (PDC ≥80%). Of 2194 eligible low-dose patients, 565 (25.8%) escalated to ≥10 mg, corresponding to 18.6% of the full cohort. CONCLUSIONS: Real-world tirzepatide persistence was suboptimal and associated with recorded starting dose. Traditional clinical comorbidities had limited impact on discontinuation timing. Nonclinical factors, including affordability, tolerability, and patient expectations, may contribute to early loss of observed treatment; although these were not directly measured.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland.
- Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland; Department of Anatomy, Jagiellonian University Medical College, Krakow, Poland.
- Institute of Medical Science, The John Paul II Catholic University of Lublin, Lublin, Poland; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.
- Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland.
- College of Medical Sciences in Warsaw, Warsaw, Poland. Electronic address: zbigniew.siudak@gmail.com.
Zitieren
APA
Dziewierz, A., Krawczyk-Ożóg, A., Szarpak, Ł., Kowalska-Bobko, I., & Siudak, Z. (2026). Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study. Advances in Medical Sciences, 71(2), 394-401. https://doi.org/10.1016/j.advms.2026.10.005
Vancouver
Dziewierz A, Krawczyk-Ożóg A, Szarpak Ł, Kowalska-Bobko I, Siudak Z. Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study. Advances in Medical Sciences. 2026;71(2):394-401. doi:10.1016/j.advms.2026.10.005
BibTeX
@article{Dziewierz2026,
author = {Dziewierz, Artur and Krawczyk-Ożóg, Agata and Szarpak, Łukasz and Kowalska-Bobko, Iwona and Siudak, Zbigniew},
title = {Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study},
journal = {Advances in Medical Sciences},
year = {2026},
volume = {71},
number = {2},
pages = {394--401},
doi = {10.1016/j.advms.2026.10.005}
}
EUVIMED